FutureFuel Corp.
FF · NYSE
Company research
FutureFuel Corp. (NYSE: FF) is a Delaware-based specialty chemicals and biofuels manufacturer that operates through its wholly-owned subsidiary, FutureFuel Chemical Company, from a 2,200-acre manufacturing facility in Batesville, Arkansas. The company conducts business across two primary segments: Chemicals, which delivers custom and performance specialty chemicals to end markets including agriculture, coatings, cleaning, oil and gas, and specialty polymers; and Biofuels, which produces and sells biodiesel and petrodiesel blends with a demonstrated plant capacity of approximately 59 million gallons per year, distributed via truck, rail, and barge across the United States. For the fiscal year ended December 31, 2023, biofuels accounted for approximately 78% of total revenues, with the remaining 22% derived from custom and performance chemical manufacturing. Headquartered in Saint Louis, Missouri, and led by CEO Roeland H. Polet since September 2024, FutureFuel employs approximately 537 full-time workers and carries a market capitalization of roughly $201 million.
Research reports
Deep, multi‑section independent research report framing FutureFuel as a high‑risk chemicals‑led turnaround, with detailed segment analysis, scenario‑based 5‑year valuation and a probability‑weighted target price around 7.07 versus ~4.11 current share price, emphasizing custom chemicals growth, customer‑funded capacity expansion, and a capital‑lite pivot away from volatile biofuels. It highlights severe cash burn, single‑site operational and regulatory risks, and structural competition from renewable diesel, but still argues for asymmetric recovery potential under base and high‑case scenarios.
Multibagger Radar (Substack) · October 14, 2025FutureFuel Corporation: A Forgotten Small Cap with Two EnginesLong‑form fundamental analysis positioning FutureFuel as an adaptable small‑cap with dual engines (specialty chemicals and biodiesel), emphasizing the flexibility of its Batesville facility to shift between fuels and chemicals, its conservative balance sheet, and embedded optionality from future policy clarity on the IRA 45Z credit. The author argues the equity value (~190 million) is well below historic mid‑cycle EBITDA potential and outlines a path to 2–4× upside if chemical margins normalize and biodiesel restarts under favorable spreads, while flagging regulatory, feedstock volatility, and small‑cap liquidity as key risks.